Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Latest filing published 11 Aug 2026 for Lyell Immunopharma, Inc., €7,706. Read the official filing
Filing timeline
BuySaleVeronica Sanchez Bulis
Insider track record
Disclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Veronica Sanchez Bulis: trading record in brief
Veronica Sanchez Bulis is a declared insider of Lyell Immunopharma, Inc., with filings sourced from SEC (Form 4). In total, 5 filings cover trades dated from 10 November 2025 to 10 August 2026.
No open-market purchase appears, only 4 sales worth €52k. Besides market trades, the filings include 1 share grant. So far in 2026, the count stands at no purchases and 3 sales.
Most recently, on 11 August 2026, the filings show an open-market sale worth €7,706 in Lyell Immunopharma, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Veronica Sanchez Bulis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
621 shares@ US$14.34Common StockSEC:0002095702-26-000005:0
217 shares@ US$18.910.0012% mcap100.0% of flowCommon StockSEC:0002095702-26-000004:0
8,750 shares0Common StockSEC:0002095702-26-000002:0
1,136 shares@ US$38.6784.5% of flowCommon StockSEC:0002095702-26-000001:0
239 shares@ US$16.1048.9% of flowCommon StockSEC:0002095702-25-000003:0
5 of 5 declarations
